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ABSTRAK (MALAY) 
Kajian ini melibatkan isu sijil halal dalam industri farmaseutikal di Malaysia. Syarikat 
yang dipilih untuk dikaji adalah Chemical Company of Malaysia Berhad (CCM Berhad). 
Syarikat tersebut merupakan sebuah syarikat farmaseutikal yang terbesar dan merupakan 
syarikat yang berada dibarisan hadapan dalam pensijilan Halal produk farmaseutikal di 
Malaysia. Dalam pembacaan yang telah dijalankan oleh pengkaji, syarikat CCM lebih 
bertumpu kepada memperolehi kelebihan persaingan di antara pesaing di dalam pasaran 
tempatan dan pasaran antarabangsa. Tujuan kajian ini adalah: (1) Membentuk barisan 
ekslusif ubatan preskripsi dan ubat-ubatan yang Halal untuk bersaing dengan pesaing (2) 
Untuk memohon kebenaran dari JAKIM I HDC bagi membolehkan produk di bawah 
CCM Pharmaceutical S.B dilabelkan dengan logo Halal pada pembungkusan produk. 
Kajian ini melihatkan kaedah kajian kes menggunakan produk farmaseutikal 
didefinisikan sebagai ubatan yang dilesenkan oleh Badan Penggubalan Undang-undang 
Perubatan yang memerlukan preskripsi sebelum memperolehinya. (1) Data premier 
seperti temuramah semi-struktur, analysis tinjauan pasaran. (2) Data sekunder seperti 
dokumen bertulis, laporan tahunan, laporan analisis industri (GMID), laman web rasmi 
yang berkaitan (seperti Kementerian Kesihatan Malaysia, lain-lain syarikat dan pesaing 
dalam pasaran) dan jumal artikel yang diterbitkan. Kaedah diagnosis yang digunakan 
dalam kajian ini adalah model SWOT dan TOWS. Kajian ini, diharap dapat 
menyumbangkan strategi yang terbaik yang boleh diadaptasi oleh CCM Berhad untuk 
menyelesaikan masalah yang dihadapi sekarang. Di samping membolehkan organisasi ini 
memperluaskan faedah konsep Halal kepada pelanggan produk farmaseutikal. Akhir 
sekali, kemungkinan di masa hadapan dengan hasil dari kajian ini boleh digunakan 
sebagai piawaian untuk memberi cadangan kepada CCM Berhad untuk mengambil 
langkah seterusnya bagi menyelesaikan masalah berkaitan kebenaran memaparkan label 
logo Halal pada pembungkusan produk. 
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ABSTRACT 
This research explores the application of Halal certification issues in the pharmaceuticals 
industry in Malaysia. The company that had been chosen for this study is Chemical 
Company of Malaysia Berhad (CCM Berhad). The CCM is the biggest pharmaceutical 
company and also at the forefront of Halal ("J~") application initiatives involving 
pharmaceuticals products in Malaysia. The company was concentrates to gaining market 
competitiveness in the local market as well as the foreign markets. The purpose of the 
study are: (1) to create an exclusive Halal certified prescription drugs or medicines line 
against its <;ompetitors (2) The key research is intended to focus on Halal "J~" 
application on pharmaceuticals product. This research employs a case study 
methodology. The key research is intended to focus on Halal "J~" application on 
pharmaceuticals product. A pharmaceutical product is defined as a licensed medicine that 
is regulated by legislation to require a prescription before it can be obtained. The data 
collection involves are: (1) primary data such as semi-structured interviews, market 
survey analysis. (2) Secondary data such as company's record, annual reports, industry 
analysis report GMID (Global Marketing Information Database), relevant website such as 
Ministry of Health Malaysia (MOH), other companies in the industry and published 
journals articles. The diagnostic tools to be need in the SWOT and TOWS models. It is 
hoped this research will contribute towards a better implementation of halal labeling for 
CCM's pharmaceutical in order to in addition this can be expand the benefits of the Halal 
("J~") concept their customers. Finally, it is envisaged that the outcome of this study 
can be used to recommend to CCM Berhad on regarding the next steps of Halal "J~" 
logo on their products packaging. 
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1.0 Background of the Case 
CHAPTER 1 
INTRODUCTION 
Currently in Malaysia, everybody is busy to talking about global Halal-hub after 
the Halal Industry Development Corporation (HDC) was a lunched in September 2006. 
Global Halal-hub is the mission that HDC is trying to achieve and that is also their main 
objective. When we talk about Halal many things will be in our mind. It might be ours 
perception of Halal, current issues about Halal, Halal products the controversy that the 
company faces about Halal issues and so on influence our minds. Because of these 
reasons, that study Halal Certification Issues in Pharmaceutical Products was chosen as a 
topic to be studied. 
The main issue is about guideline or Halal certification procedure in Halal 
pharmaceutical product. Under pharmaceutical products categories one of the category is 
medicines. Medicine has been categories as a consumable product which is can be taken 
to eat or apply at human body. The current scenario that happening in market is most of 
the kinds of pharmaceutical products had displays Halal logo at product packaging and at 
the same time those product has obtain Halal certification. As a Muslims consumer, the 
consumer will find the Halal pharmaceutical product that has been certified Halal 
product. It also is fulfilling the requirement of Syariah laws of Halal. But in the guideline 
and procedure in JAKIM/ HDC stated, pharmaceutical product (medicines) will be 
rejected for Halal certification application. 
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Firstly, this study will focus on the Chemical Company of Malaysia Berhad 
(CCM) as a reference and benchmark of a pharmaceutical company. By using CCM, the 
main study is to determine the issues that arise regarding Halal certification in Halal 
pharmaceutical products. With reference to Manual Prosedur Pensijilan Halal Malaysia 
book (2005) 1st edition, published by Jabatan Kemajuan Islam Malaysia (JAKIM), 
application for Halal Certification by (JAKIM) will be rejected it does not follow the 
requirements they as stated in the manual. One of the requirements stated was related to 
pharmaceutical products. All kinds of drugs or medicines that are categorized as 
pharmaceutical products by the Ministry Health of Malaysia (Kementerian Kesihatan 
Malaysia) will be rejected for the application. 
If these conditions were to be applied in the Malaysian industry, then how do the 
pharmaceutical companies run their business without the halal logo? And how do we 
determine and categorize whether the pharmaceutical products are listed under the under 
Ministry of Health (MOH) and will all those products be rejected? This question is more 
relevant to CCM itself Then the next issue is the role of JAKIM. As we known HDC has 
taken over the JAKIM the in terms ofHalal certification. The main question is why is it 
that, JAKIM/HDC could not accept the application from producer's pharmaceutical of 
products. Pharmaceuticals products are also consumable products that are categorized as 
Halal products in market. 
In the market some of the pharmaceutical products display the Halal logo on the 
packaging but some do not. This will cause confusion among the consumers. For 
example same of the CCM, products listed under the HDC have the Halal logo on the 
packaging but some do not. So this study will focus on these issues and try to find the 
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answers to all the questions that arise. Hopefully this study will find the reasonable 
answers and to eliminate confusion regarding the issue among in consumers generally. 
Consumer has been confused because some of the pharmaceutical products in market had 
displays Halal logo and some not displaying. This brings more confused if the consumer 
check and refer to HOC website which is has a listed of pharmaceutical products that has 
been certified Halal by HDC. When the consumers refer to that lists some of the products 
that were listed at market not displaying the Halal logo whether the product has Halal 
certification. 
1.1 Problem Statement 
The problem in these studies can be divided into two. First the problems, related 
to CCM Berhad and the second related to HOC. The main issue that these two companies 
faced is related to Halal certification of pharmaceutical products in-term of guideline and 
procedure, but in this study or case the main issue will be highlighted towards to CCM 
Berhad Company. The main focus is to look in depth toward to CCM Berhad Company 
business activities that related with Halal issues. This study will try to focus on the best 
strategy that can adopted by CCM Berhad to solve their problems regarding Halal 
certification of their products and at the same time to emphasize their opportunities in the 
industry and market by giving them competitive advantage among the rivals. This 
strategy may perhaps help the company to expand their business effectively and 
efficiently through the entire world of Halal pharmaceutical products. HOC is the 
organization as a reference (body authority) that control Halal certification in Malaysia. 
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1.2 Issues to Be Examined In the Case 
1. To know why the Halal certification application for all kinds of medicinal products 
under the Ministry of Health (MOH) list will be rejected. What is the reason? 
2. To recommend JAK.IM!HDC that they should allow the pharmaceutical company 
displaying Halal logo on product packaging if the product was certified Halal by 
JAKIM/HDC. 
3. To determine the responsibility ofHDC after having taken over the role from JAKIM 
in terms ofHalal certification? (What is the function, rules, procedure, integrity and etc). 
4 
CHAPTER2 
LITERATURE REVIEW 
INDUSTRY PROFILE 
2.0 Pharmaceuticals Industry 
2.1 History 
The pharmaceutical industry is highly regulated. Companies in this industry are 
subjected to a variety of laws and regulations relating to their products such as the 
research and development activities, testing methods, manufacturing processes, 
marketing, sales and distribution. Pharmaceutical industry provides innovator drugs, 
generics and health/dietary supplements. Innovator drugs are those with patent protection 
for their active ingredients or process. Generic drugs contain the same active ingredients 
as that of innovators' but may not necessarily be of the same formulation. Pharmaceutical 
companies also produce medicine. Medicine define as a substance used to prevent or cure 
disease or to relieve pain, anxiety or any form of perceived discomfort categories as 
prescriptive (ethical) and over-the-counter. 
The pharmaceutical industry started in the l91h century. At that time, humans 
believe that plants, animals and minerals contained medicinal properties, which is the 
intuition and trial and error was the methods that have been used. The oldest records of 
medicinal preparations made from plants, animals or minerals are those of the early 
Chinese, Hindu and Mediterranean civilizations. Meanwhile for Alexandria, Egypt era in 
the 2nd century relatively purified inorganic chemicals such as lead carbonate, arsenic and 
5 
mercmy. In the previous century 1st one of Greek physician has found a few medical 
agents example verdigris and cupric sulfate as prescribed as medicinal medicine. 
For the earliest drugstore was found in Middle Ages was opened by Arabian 
pharmaceuticals in Baghdad in 754. Starting from this point, many stores soon began 
operating throughout the medieval Islamic world and also Europe. During 1950s and 
1960s numerous new drugs were developed this included first oral contraceptive (The 
pills), Cortisone, blood pressure drugs and other heart medications. At the same time, 
legislation was enacted to test/examine and approve drugs required for labeling. The 
medicine also was classified as prescription and non-prescription drugs became legally 
pharmaceuticals product. 
In 1964, the World Medical Association was established to set standards for 
clinical research and demanded that subject give their informed consent before enrolling 
in an experiment. Pharmaceutical companies at that time were required to prove efficacy 
in clinical trials before marketing drugs. Entered to the 1980s, pressure by economics and 
a new regulations body or institute both safety and environmental but also transformed 
new DNA chemistries and new technology was growth in proper ways. Pharmaceuticals 
industries also get a new impact whereby a dramatic increase in the use of contract 
research organizations for clinic development and even for basis R&D. 
So from the history, the medicine was developing from raw material (plants) and 
to drug medicine product with scientific name. Until today, the sources are still being 
used and the physician are still doing researches to explore content of that sources that 
might be have other medical agents which can be used to cure or make as a new 
medicine- get the new potential. Drug development was in progress from hit and mass 
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approach to rational drug in laboratory design and natural product. Lately after many 
technologies that have been used producers are producing and creating products that are 
demand by consumers such as nutritional supplements otherwise known as alternative 
medicine. According to the latest figure there are now more than 200 maJor 
pharmaceutical companies Ill industry. Source from: 
( 
.) 
2.2 Definition 
According to Wikipedia, "Pharmaceutical Company is a commercial business 
whose focus is to research, develop, produce to market and distribute medicines. 
Pharmaceutical companies can deal in generic and/or brand medications. They are subject to a 
variety of laws and regulations regarding the patenting, testing and marketing of drugs.'" Source 
from: ( ) 
2.3 Global Company 
On the year 2007, the companies which were listed as the top 5 Pharmaceutical 
Company are: (1) Johnson & Johnson (J&J) which comprises the world's premier 
consumer health company, the world's largest and most diverse medical devices and 
diagnostics company, the world's third-largest biological company and the world's sixth-
largest pharmaceutical company. Johnson & Johnson was incorporated in 1887 and its 
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Worldwide headquarters is in New Brunswick, New Jersey, USA J&J have more than 
250 operating companies and employing 119,400 who are people engaged in research 
and development, manufacture and sale of a range of products in the healthcare field. The 
company operates in three different segments: (1) consumer, (2) pharmaceutical and (3) 
medical devices and diagnostics. 
Pfizer Inc is the second world's largest pharmaceutical company. The company 
operates in consumer healthcare and animal health products in addition to its core 
pharmaceuticals. Pfizer's consumer healthcare division operates in OTC healthcare 
market worldwide across all major sectors. The company's key product is cough, cold 
and allergy (hay fever) remedies brands such as Benadryl and Sudafed. The company 
also holds large value share in Nicorette brand, Zantac (digestive remedies, Rogaine I 
Regaine in medicated skin care and Visine in eye care. Recently its New York based 
company produced high selling medicines and drugs which include the famous Viagra 
pills. 
The third is Bayer AG Company whose headquarters is located at Bayerwerk, 
Leverkusen Germany. The company produces diversified chemicals, pharmaceuticals, 
dietetic products and hygiene products. Fourth is GlaxoSmithKiine (GSK) Company 
based in UK, London. GSK has been as a leading research based Pharmaceutical 
Company operating in consumer healthcare, cosmetics and toiletries and non-alcoholic 
drinks in addition to its core pharmaceuticals. The company has its operational 
headquarters in the US and operates in over 117 countries and sell products in over 140 
countries. The key product is Panadol in analgesics for its healthcare business and the last 
is Novartis AG based at Basel, Switzerland. Norvatis has been merger with the Swiss 
pharmaceuticals companies ClBA-GEIGY and Sandoz. In 1996, Norvatis was fonned and has 
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smce become one of the world's leading manufacturers of phannaceuticals and consumer 
healthcare products. Norvatis business activities are manufacture of phannaceuticals, agricultural 
chemicals, hot drinks and packaged foods. (Source from: 
) 
2.4 Industry Revenues Year 2006 
2.4.1 Global Market Leaders In Terms of Revenue 
The table below shows a list of large pharmaceutical and biotech companies ranked by 
healthcare revenue in (USD million) worldwide. 
Table 2.1 
Total Revenues of Market Leaders (USD Million) Year 2006 
Revenue Total Healthcare Net Employees 
Rank Revenues R&D 2006 income/ 2006 
2006 Company Country loss 2006 
1 Johnson and USA $53.324 $7,125 $ll,053 $138,00 
Johnson (J&J) 
2 Pfizer USA 48,371 7,599 19,337 122,200 
3 Bayer Germany 44,200 1,791 6,450 I 06,200 
4 G laxoSmithK.linc United 42,813 6,373 10,135 106,000 
Kingdom 
5 Novartis Switzerland 37,020 5,349 7,202 102,695 
6 Sanofi-A ventis France 35,645 5,565 5,033 100,735 
7 Hoffman-La Switzerland 33,547 5,258 7,318 100,289 
9 
Roche 
8 AstraZenecca UK/Swedcn 26,475 3,902 6J)63 98,000 
9 Merck & Co. USA 22,636 4,783 4,434 74,372 
10 Abbott USA 22,476 2,255 1,717 66,800 
Laboratories 
Source: Wikipedia encyclopedia- Pharmaceutical industry 
Figure 2.1 
Total Revenues ofrnarket leaders (USD Million) year 2006 
Total Re.·mue; d nnrktt lea:lffs lyymr2cx:X) 
$22,63Sl 
$26 ,475--,_. •' . ,, 
r~.324 
$37.aw $42.813 
_______ ,. ______ -------, 
IJB~ , DS~fi-Avcntis I 
CMerck&Ol. I 
i[ii~lnSJ~~~)~---- -i::iffrt~d---
I OGiaxo..'>lrithKl ine ONovartis 
II 
CHoffimrn-LaRccl-e CA~IIllZ.encca 
. UAbl:xltt Lal.n!'atcrics 
Source: Wikipedia encyclopedia Pharmaceutical industry 
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2.4.2 Global Market Leaders in Terms of Sales 
Below has shown table of the lists oftop ten pharmaceutical companies by 2006 sales in 
USD Million. 
Table 2.2 
Market Leader in Terms of Sales (USD Million) Year 2006 
Rank Company Sales Growth Market Based/Headquartered in 
($m) (%) Share(%) 
1 Pfizer 45,983 2.1 7.3 us 
2 GlaxoSmithKline 37,034 9.7 5.9 UK 
3 Sanofi-Aventis 35,638 5.0 5.7 France 
4 Novartis 28,880 18.0 4.6 Switzerland 
5 Hoffmann-LaRoche 26,596 21.8 4.2 Switzerland 
6 AstraZeneca 25,741 10.5 4.1 UK/ Sweden 
7 Johnson & Johnson 23,267 4.2 3.7 us 
8 Merck& Co. 22,636 2.8 3.6 us 
9 Wyeth 15,683 2.4 2.5 us 
10 Eli Lily and 14,814 7.5 2.4 us 
company 
Source: Wikipedia encyclopedia- Pharmaceutical industry 
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Figure 2.2 
Market Leaders in Terms (dSales (USD Million) 2006 
1\Iarket Leader in terms of Sales by 2006 
$23 
$26,596 
ONorvatis I DPfizer 0 Johns on& J o!Uls on OEli Lilly and Company 
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$28,880 
0 GlaxoSmitil:Kline 
0 Hoffmann-LaRoche 
DMerck & Co. 
$37,034 
l 
$35,638 
OSauo -A nntis 
OA.stJ·aZeneca 
OWyeth 
Source: Wikipedia encyclopedia- Pharmaceutical industry 
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2.4.3 Market Leader Growth(%) Year 2006 
Figure 2.3 
Market leader's growth (%) in percentage by ·year 2006 
25 ,., 
20 
.-n 
I .-r-
I __ 15 1-
10 1- r-
r-r-
5 1- 1- t-
,--,-
0 fT [[ m 
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Aventis Z€:teca I C.;:. : 
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Source: Wikipedia encyclopedia- Pharmaceutical industry 
Figure 2.4 
Market Leaders in term of Market Share(%) 2006 
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Source: Wikipedia encyclopedia- Pharmaceutical industry 
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2.5 Malaysia Pharmaceutical Industry 
Referring to Malaysia Industrial Development Authority (MIDA), Malaysian 
pharmaceutical manufacturers have produced medicines in dosages of all forms e.g. 
tablets (coated & non-coated), capsules (hard and soft gelatin), liquids, creams, 
ointments, small volume injectables, dry powders and active pharmaceutical ingredients. 
The local industry is producing about 30 per cent of the domestic demand, as well as 
exporting to the Asia-Pacific countries, the Middle East, Latin America and Europe. 
Total exports in 2008 amounted to RM513 million (USD$142 million). Currently, a total 
of 234 pharmaceutical companies with Good Manufacturing Practice (GMP) certification 
have registered with Drug Control Authority (DCA). A total of 6 7 companies are 
involved in the production of modem medicines and 167 companies are local traditional 
and herbal medicine manufacturers. Source from 
( ) 
The prominent market research firm estimates that the Malaysia pharmaceutical industry, 
which is valued at $1.03 billion (RM3 .23 billion) in 2007, will record a compound annual 
growth rate of 10.5% and reach the $1.8 billion mark by 2013. Main growth is expected 
to be seen in generic medication, therapy, over-the-counter (OTC) and traditional & 
herbal supplements. The generic products and medication will continue to be major 
source of medication with the government set to become the main purchaser from the 
pharmaceutical companies. More general hospitals are also being built and it is only 
natural that the demand for the generic medications increases for public consumption. 
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Source from: ( 
) 
On the other hand, the potential of the domestic pharmaceutical industry has been 
recognized by the Malaysian government who has identified it as a strategic industry 
which should be promoted. In Malaysia pharmaceuticals industry, Malaysia Organization 
of Pharmaceutical (MOPI) plays an important role to their memberships that are from 
manufacture pharmaceuticals. MOPI's membership is restricted to manufacturers with 
factories in Malaysia that are licensed by the DCA, Ministry of Health, to manufacture 
pharmaceuticals. MOPI's functions are to co-operate with the government and other 
bodies, represent the interests of the pharmaceutical industry, promotion and 
development of the industry, facilitate and encourage the development, exchange and 
transfer of information and technology, domestically and internationally and promote and 
facilitate orderly trade in life science products. According to Malaysia organization of 
pharmaceutical (MOPI) pharmaceutical products can be broadly categorized as a below: 
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Figure 2.5 
Categories of Pharmaceutical Products in Malaysia 
Pharmaceutical Products in Malaysia 
~ I I 1 Prescription 
Over -the-counter Traditional Health and Food 
(OTC) medicines Supplement 
Source: Malaysia Organization of Pharmaceutical Industries-
The industry can now produce almost 80% of the vanous categories m the 
Malaysian Essential Drugs List. In 1998, the government registered 7,416 prescription 
medicines and 8,873 OTC medicines while about 20,000 applications for traditional 
medicines were received. Source from: (Malaysia Organisation Pharmaceutical Industry 
) 
A prescription drug is a licensed medicine that is regulated by legislation to 
require a prescription before it can be obtained. The term is used to distinguish it from 
over-the-counter drugs which can be obtained without a prescription. Different 
jurisdictions have different definitions of what constitutes a prescription drug. 
Dispensation of prescription drugs often includes a package inserted (a Patient 
Information Leaflet or PIL) with detailed information about the drug. The prescription 
medicines comprise patented and generic drugs, the sale and transaction of which are 
confined to doctors and pharmacists. 
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Over-the-counter (OTC) products are these which can be obtained without a 
prescription. The OTC, traditional medicines and health/food supplements may be sold 
by non-professional outlets and to members of the public. They are used to treat 
conditions not necessarily requiring care from a health care professional and have been 
proven to meet higher safety standards for self-medication by patients. OTC products are 
products such as Adult mouth care; Allergy care; Analgesics; Calming and sleeping 
products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; 
Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; 
NRT Smoking cessation aids; OTC obesity; OTC statins; OTC triptans; and Vitamins and 
dietary supplements. 
Traditional medicines refer to health practices, approaches, knowledge and beliefs 
incorporating plants, animals and mineral based medicines, spiritual therapies, manual 
techniques and exercises, applied singularly or in combination to treat, diagnose and 
prevent illnesses or maintain well-being. Traditional medicines are also known as 
Complementary or Alternative Medicines (CAM). Traditional medicines are allowed to 
be sold as over the counter medicines without any restrictions. Limited health claims may 
be made. Malaysia does not have any national pharmacopoeia. However, international 
pharmacopoeia such as The Chinese pharmacopeia and the Pharmacopeia of India are 
used as references but are not considered legally binding. Health and food supplement is 
a preparation intended to supply nutrients, such as vitamins, minerals, fatty acids or 
amino acids, that are missing or are not consumed in sufficient quantity in a person's diet 
Pharmaceutical Practice and law in Malaysia are regulated by the Drug Control 
Authority (DCA) in Malaysia, under the Control of Drugs and Cosmetic.~ Regulations 
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1984. The DCA is managed by the Director General of Health, Director of 
Pharmaceutical Services, Director of the National Pharmaceutical Control Laboratory, 
and seven other appointed members. The main responsibility of the DCA is to ensure the 
safety, quality and efficacy of pharmaceuticals in Malaysia. Some of the DCA's duties 
include: 
(I) Reviewing registration applications for drugs and cosmetics; 
(2) Licensing importers, manufacturers and wholesalers; 
(3) Post-marketing safety surveillance and 
(4) Adverse drug reaction (ADR) monitoring. 
According to the DCA, any drug in a pharmaceutical dosage form, intended to be 
used, or capable or purported or claimed to be capable of being used on humans or 
animals, whether internally or externally, for a medicinal purpose is required to be 
registered with the DCA This includes products which alleviate, treat or cure diseases, 
products that diagnose a disease, anesthetics, and products that maintain, modify, prevent, 
restore or interfere with normal physiological functions. Source from: Pharmaceutical 
Service Division of the Malaysia Ministry of Health. Source from 
2.6 Pharmaceutical Industry in term of Market Shar'e 
The Malaysian pharmaceutical industry is expanding at a high rate and has 
amounted to USD652.8 million by the end of2007. In 2000 and 2005, the pharmaceutical 
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industry was only at USD315 .8 and 539.5 million respectively. Today there are around 
300 registered pharmaceutical companies in Malaysia, of which 100 are local. The top 40 
pharmaceutical companies hold some 30% of the market share. Large local 
manufacturers, which fall within the top 40 include UPHA, a wholly owned subsidiary of 
listed entity Chemical Co. of Malaysia Bhd., and Raza Manufacturing, 100% owned by 
Pharmaniaga Bhd. Other significantly large local pharmaceutical companies include YSP 
Industries, Duo Pharma and Xepa-Soul Pattison. The Malaysian pharmaceutical industry 
is expanding at an average of 10% annually. The market share held by Malaysian 
companies is growing and they now hold between 20 and 30% of the market compared to 
ten years ago, where they only held some l 0 to 15% of the market. Multinational 
corporations (MNCs) control about 70% of the pharmaceutical market. Source from 
2.7 Drug Application Process 
There are three types of applications for drug approval in Malaysia: (1) 
application for an innovator product, (2) application for a generic drug, and (3) abridged 
application. An application for an innovator drug includes drugs containing a new 
chemical or biological entity, or a new combination of existing chemicals/biological. 
Changes in product composition or characteristics (such as color, shade, flavor, fragrance 
or shape) will also require a new registration application. Conversely, a change in product 
name, specifications, packaging, indications, labeling, package insert, product literature, 
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or excipients only requires an abridged application, which must be submitted to the DCA 
prior to making the change(s ). 
Product registration for imported products will reqmre additional documents and 
information, including: 
• Certificate of Pharmaceutical Product (CPP) from the pharmaceutical authority in 
the country of origin. (If a CPP is not available, a GMP certificate or 
manufacturing license is generally acceptable along with either a (1) CPP from 
the country of the product owner or (2) CPP from country of release.) 
• Alternatively, traditional medicines, dietary supplements, and external personal 
care products require a Free Sale Certificate and Good Manufacturing Practice 
(GMP) certificate. 
A separate application is required for each product to be registered. Products with the 
same ingredients but different specifications, such as the amount of ingredient(s ), dosage 
forms, descriptions, manufacturer, etc., will require a separate application for each 
product registration. Products differing only in their packaging materials or pack sizes 
can be registered m a single product application. Source from: 
( ) 
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2.8 Halal Industry 
In the Ninth Malaysia Plan (RMK-9), 2006-20 l 0 Malaysia will be developed as a 
centre for the certification of Halal products and the JAKIM certification will be 
promoted worldwide. Halal is significantly related with Muslim population. Statistics 
have shown how the huge Muslim population in the world will provide big opportunities 
for companies or business entities involved with Halal industry to grab the profit from 
Muslim population. The statistics in the year 2008, have shown that the Muslim 
population is (l.billion) out of the world population of the population of ( 6. 7 billion). In 
percentage it is 24.31% and the Muslim population estimated for year 2009 will be 
increasing at I .84% or (1657.6 million). For Malaysia specifically (Asia Pacific), the total 
population is 25,715,819 million (July 2009 est). The Malay population is (50.4%) and 
Muslim is (60.4%). Based on the Muslim population figures the opportunities are there 
for the Halal industry. Source from: 
Malaysia is not in the forefront in Halal industry and also it is not the only country 
that participates in the halal food industry or generally Halal industry. Others competitors 
like India, Australia, New Zealand and Brazil have already created names in the Halal 
food industry. For example Australia is the largest exporter of Halal red meat, India the 
largest exporter of Halal chicken and New Zealand the largest exporter of Halal lamb. 
The difference between these countries and Malaysia are (1) these countries just have a 
small Muslim population axcept India but yet they can be the largest exporters in halal 
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food (2) among the countries/competitors none of them has a government which gives 
full support to the development of the Halal sector. 
Many agencies and institutions are involved in the development of the Halal 
industry. To promote the development of the Halal industry, coordination among the 
ministries and agencies will be further enhanced. The main agency that is responsible is 
Ministry of International Trade and Industry (MITI). MITI is responsible in bringing-out 
the Halal industry to international/ global market. MITI had set-up strategies and policies 
towards global Halal hub. Its means Malaysia will be the base of operations for the 
industry. In the near future MITI aims, to make Malaysia the centre for the production, 
Halal service providers, reference on the Halal standard and R&D on Halal matters. MITI 
had set up eleven strategies purposely for the development and promotion of Malaysia as 
'Global Halal Hub'. 
1. Enhancing the awareness on Malaysia as the centre for Halal products and 
services 
2. Managing the increasing competition from countries in the region 
3. Leveraging upon outward investments to gain access to raw materials and 
enhance competitiveness 
4. Enhancing R&D in product and process developments and leveraging upon latest 
technological developments to expand the product range 
5. Developing Halal-compliant services 
6. Utilizing and leveraging upon Malaysian Halal Standard to differentiate 
Malaysia's Halal products 
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7. Undertaking systematic development ofhalal parks 
8. Ensuring product quality and food safety 
9. Harmonizing the Halal certification process 
10. Enhancing the coordination and of organization among agencies involved in the 
development and promotion of the industry 
11. Strengthening the institutional capacity of organization involved m the 
development and promotion of Halal products and services. 
To achieve the above strategies MITI has made collaboration with other 
government and private agencies. Malaysia External Trade Development Corporation 
(MATRADE) is responsible for enhancing MATRADE'S capabilities in gathering 
market intelligence for new and emerging markets and encouraging. Malaysian food and 
non-food companies acquire marketing capabilities, to expand their operations in 
identified markets including the establishment of Malaysia food outlets overseas. 
Tourism Malaysia and MATREDE also collaborate to develop specific programmes to 
promote Malaysia Halal food products and encourage Malaysian Halal food and non-
food companies to foreign countries. 
Research and development is needed to growing Halal market, so the industry 
will be encouraged to achieve a higher level of innovation in product and process 
developments in both the food and non-food industries. SMEs assisting involved in Halal 
food and non-food production, in acquiring the necessary technological capabilities to 
upgrade their manufacturing processes, enhance product development and improvements. 
Small and Medium Industries Development Corporation (SMIDEC) are also responsible 
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for the development and capacity building of SME's and the Department of Standards 
Malaysia will coordinate the development of the Malaysia Halal Standards. 
Before the RMK-9, JAKIM was the agency that fully was responsible for the 
Halal standard and certification. Before HDC was established, the objective of JAKIM 
was to upgrade and to enable it to provide more efficient services to the industry, both at 
the domestic and international level. To enhance the abilities and emphasize Halal 
industry HDC was establish on 18 September 2006 with objective to coordinate the 
overall development of the industry. Source from: MITI 
2.9 CCM Pharmaceuticals Sdn Bbd Analysis 
CCM Pharmaceuticals is under the CCM Berhad Company. It's one of CCM 
Berhad major subsidiaries. CCM Pharmaceuticals was a leader company in 
pharmaceuticals industry. In Malaysia, the OTC healthcare and health wellness industry 
is still growing and remained as the review period. The presences of few domestic and 
multinational competitors have made some impact to cause their stability in the market. 
In 2007, CCM Pharmaceuticals ranked 24 with only a l percent value share. The 
company has increased its stake in the OTC healthcare and health wellness healthcare 
industry. During the year 2006, the company was acquired Malayan Pharmaceuticals by 
its parent company the Chemical Company of Malaysia. The acquisition was a success 
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